Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PFSB Begins Discussions Toward Lifting Ban on Subcontracting of Safety Management Tasks
December 12, 2013
- MHLW Notifies Authorities of Expiration Date Extension for Relenza from 7 to 10 Years
December 12, 2013
- 3-Drug Therapy Including Simeprevir for Chronic Hepatitis C to Be Eligible for Medical Expense Assistance: MHLW
December 11, 2013
- September Price Settlement Rate at 73.5%; Low Figure Blamed on Pharmacy Chains
December 10, 2013
- Japan Diet Enacts Bill to Open Door for Online OTC Drug Sales
December 10, 2013
- FPMAJ OKs Concession Plan on Key Premium; Bill Payers Stick to Opposition
December 9, 2013
- Average Drug Price Discrepancy Rate at 8.2%: Health Ministry
December 9, 2013
- PMDA Aims to Solidify Partnerships with Overseas Regulators via February Symposium
December 9, 2013
- MHLW to Make Additional Appeal for Applicants for Special Grants to Produce Vaccines for New Strains of Influenza
December 6, 2013
- MHLW Calls for Caution on ADRs Associated with Axitinib, Bevacizumab
December 6, 2013
- Revision of Notification on Advanced Healthcare Introduces New Rules for Anticancer Drugs
December 5, 2013
- Would Proposed New Rule for Repricing Long-Listed Drugs Create Winners and Losers? Bill Payers Opposed, Industry Watching Closely
December 5, 2013
- PAFSC’s First Committee Backs Japan’s 1st SGLT-2 Inhibitor
December 2, 2013
- 11 APIs/33 Products Including ComPlavin Added to NHI Price List
December 2, 2013
- PFSB Issues Notification Calling for Revisions of Package Inserts for Drugs Including Aricept, Cravit
December 2, 2013
- Toned-Down Proposal on “Precursor” Premium Still Leaves CSIMC Wary; 10% Tabled with Strings Attached
November 29, 2013
- New Proposals by Regulatory Reform Council Include Elimination of 14-Day Prescription Limit
November 29, 2013
- New Combination Drugs Containing Non-Innovative APIs Should Be Priced Based on Prices of Other APIs Contained: CSIMC Subcommittee
November 29, 2013
- CSIMC Bill Payer Rep Repeats Opposition to Replacing Special Price Cut for Off-Patent Drugs with New Rule
November 28, 2013
- Ministry Revises Plan to Set First Generic Prices, Suggests 50% or 60%
November 28, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…